Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $400,000, reflecting ongoing progress in partnered programs [23] - Research and development expenses increased to $19.2 million from $18 million in the prior year, driven by external program advancements [24] - Selling, general, and administrative expenses decreased to $8.4 million from $9.3 million in the prior year, primarily due to reduced personnel-related expenses [24] - Cash, cash equivalents, and marketable securities rose to $152.5 million as of September 30, 2025, compared to $117.5 million as of June 30, 2025, indicating a strong financial position [24] Business Line Data and Key Metrics Changes - The company is prioritizing the development of ABS-201 for both androgenetic alopecia (AGA) and endometriosis, reallocating resources from ABS-101 [6][15] - ABS-201's development for AGA is on track, with a phase one/two A trial expected to initiate in December 2025 [5][9] - The company plans to initiate a phase two proof of concept clinical trial for ABS-201 in endometriosis in Q4 2026, highlighting the dual development strategy [5][22] Market Data and Key Metrics Changes - The market opportunity for ABS-201 in both AGA and endometriosis is characterized by significant unmet medical needs and poor standard of care, with both indications representing multi-billion dollar markets [8][18] - The company aims to leverage shared phase I development for ABS-201 to enhance clinical trial efficiency and speed [8] Company Strategy and Development Direction - The strategic decision to focus on ABS-201 reflects a disciplined approach to capital allocation, aiming to maximize value creation for shareholders [6][15] - The company is expanding its AI platform capabilities to enhance preclinical R&D and generate partnership interest [14] - Plans to sign one or more drug creation partnerships with large pharmaceutical companies by year-end are in place [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ABS-201, emphasizing its best-in-class profile and the significant market opportunities in AGA and endometriosis [8][26] - The company is excited about the upcoming KOL seminar on December 11, where further details on ABS-201 will be shared [12][27] Other Important Information - The interim results from the ABS-101 phase I trial showed a favorable safety profile with no serious adverse events reported [4] - The company is also progressing additional programs, including ABS-301 and ABS-501, which are intended for partnership prior to clinical development [13][23] Q&A Session Summary Question: Details on TL1A program and endometriosis - Management confirmed that while the half-life of ABS-101 was extended compared to first-generation competitors, it fell short of second-generation programs, leading to a strategic shift towards ABS-201 for endometriosis [29][30] Question: Competitive landscape for endometriosis trial design - Management noted that the endometriosis indication is less competitive than IBD, and they are focused on a well-structured trial design to ensure robust data [31] Question: Partnering status for ABS-101 - The company plans to share recent data with potential partners in the coming weeks and is exploring first-in-class indications for ABS-101 [32][33] Question: Recruitment for AGA trial - Management expressed confidence in recruiting for the AGA trial, with multiple sites engaged and a KOL event planned to support recruitment efforts [41] Question: Efficacy timeline for AGA trial - An interim readout for the AGA trial is expected in the second half of next year, focusing on safety and tolerability [41] Question: Insights from competitor HMI-115 trial - Management highlighted the encouraging proof of concept from the HMI-115 trial, which supports the mechanism of action for ABS-201 in endometriosis [47][48] Question: Potential for ABS-201 in additional indications - While the focus remains on AGA and endometriosis, management acknowledged the potential for ABS-201 to be expanded to additional indications in the future [50]

Core Insights - Absci Corporation is focusing on advancing its ABS-201 program for androgenetic alopecia and endometriosis, which are high-value indications with significant unmet medical needs [2][5][6] - The company reported interim results for its ABS-101 Phase 1 trial, showing an extended half-life compared to competitors and no serious adverse events [5][6] - Absci's financial position is strong, with sufficient cash and marketable securities to fund operations into the first half of 2028 [7][11] Pipeline Updates - The Phase 1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) is set to begin in December 2025, with an interim efficacy readout expected in the second half of 2026 [5][6] - The company plans to initiate a Phase 2 clinical trial for ABS-201 targeting endometriosis in Q4 2026, with a potential proof-of-concept readout in the second half of 2027 [6][7] - Absci is reallocating resources from ABS-101 to accelerate the development of ABS-201, reflecting a strategic shift towards indications with higher market potential [2][5] Financial Performance - For Q3 2025, Absci reported revenue of $0.4 million, a decrease from $1.7 million in Q3 2024 [8] - Research and development expenses increased to $19.2 million in Q3 2025 from $18.0 million in Q3 2024, driven by advancements in internal programs [9] - The net loss for Q3 2025 was $28.7 million, compared to a net loss of $27.4 million in Q3 2024 [10]